Academic Bibliography

Search 200 years of publications by Ghent University researchers.

prof. Vibeke Kruse

Faculty of Medicine and Health Sciences > Department of Internal Medicine and Pediatrics

Work address: C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent
Email: VIBEKE.KRUSE@UGent.be

Show Sort by

Add to list
Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma

Nora Sundahl, Teofila Seremet, Jo Van Dorpe (UGent) , Bart Neyns, Liesbeth Ferdinande, Annabel Meireson (UGent) , Lieve Brochez (UGent) , Vibeke Kruse (UGent) and Piet Ost (UGent)

(2019) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 104(4). p.828-835
Add to list
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition

Stijn De Keukeleire (UGent) , Tijl Vermassen (UGent) , Gert De Schoenmakere, Vibeke Kruse (UGent) , Karim Vermaelen (UGent) and Sylvie Rottey (UGent)

(2019) ACTA CLINICA BELGICA.
Add to list
- Journal Article
- A1
- open access
Throughput efficiency and service quality after process redesign at a cancer day care unit: Two sides of the coin?

Kaat De Pourcq (UGent) , Paul Gemmel (UGent) , Jeroen Trybou (UGent) and Vibeke Kruse (UGent)

(2019) EUROPEAN JOURNAL OF CANCER CARE. 28(1).
Add to list
- Journal Article
- A1
- open access
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Lieve Brochez (UGent) , Annabel Meireson (UGent) , INES CHEVOLET (UGent) , Nora Sundahl, Piet Ost (UGent) and Vibeke Kruse (UGent)

(2018) NATURE COMMUNICATIONS. 9.
Add to list
- Journal Article
- A2
- open access
Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor : case report and literature review

Marlies De Bock, Eva Hulstaert (UGent) , Vibeke Kruse (UGent) and Lieve Brochez (UGent)

(2018) CASE REPORTS IN DERMATOLOGY. 10(2). p.190-197
Add to list
- Conference Paper
- C3
Endothelial indoleamine 2,3-dioxygenase is correlated with microsatellite status in colorectal carcinoma and predicts worse prognosis

Annabel Meireson (UGent) , INES CHEVOLET (UGent) , Eva Hulstaert (UGent) , Liesbeth Ferdinande (UGent) , Piet Ost (UGent) , Karen Geboes (UGent) , Marc De Man, Dirk Van de Putte, Laurine Verset, Vibeke Kruse (UGent) , et al.

(2018) OncoPoint, 6th Research seminar, Abstracts.
Add to list
Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma

Nora Sundahl, Katrien De Wolf, Vibeke Kruse (UGent) , Annabel Meireson (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Mireille Van Gele (UGent) , Reinhart Speeckaert (UGent) , Benjamin Hennart, Lieve Brochez (UGent) , et al.

(2018) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 100(4). p.906-915
Add to list
- Journal Article
- A2
- open access
Peritumoral endothelial indoleamine 2,3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile

Annabel Meireson (UGent) , INES CHEVOLET (UGent) , Eva Hulstaert (UGent) , Liesbeth Ferdinande (UGent) , Piet Ost (UGent) , Karen Geboes (UGent) , Marc De Man (UGent) , Dirk Van de Putte (UGent) , Laurine Verset, Vibeke Kruse (UGent) , et al.

(2018) ONCOTARGET. 9(38). p.25216-25224
Add to list
The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital

Barbara Claus (UGent) , Kaat De Pourcq (UGent) , Nele Clottens (UGent) , Vibeke Kruse (UGent) , Paul Gemmel (UGent) and Johan Vandenbroucke (UGent)

(2018) EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE. 25(6). p.334-336
Add to list
Cost-effectiveness and budget effect analysis of a population-based skin cancer screening

Lore Pil (UGent) , Isabelle Hoorens (UGent) , Katrien Vossaert (UGent) , Vibeke Kruse (UGent) , Isabelle Tromme, Niko Speybroeck, Lieven Annemans (UGent) and Lieve Brochez (UGent)

(2017) JAMA DERMATOLOGY. 153(2). p.147-153

1
2

Next →